The DEVOTE cardiovascular outcomes trial comparing insulin degludec (degludec) versus insulin glargine 100 U/mL (glargine U100) in a type 2 diabetes (T2D) population included many participants with 8-point glucose profiles and adjudicated events. The gene discussed is INS; the disease is type 2 diabetes mellitus.